Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.

talabostat (BXCL701) - BioXcel

Keytruda (pembrolizumab) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42114950

Dan Costin; Daniel P Petrylak; Jiaoti Huang; Jingsong Zhang; Johann de Bono; Lawrence I Karsh; Li Zhang; Mark Linch; Moses Donkor; Pascal Borderies; Paul Monk; Rahul Aggarwal; Rashmi Deshpande; Rob Jones; Scott Tagawa; Vincent O'Neill; Xinhua Zhu

May 12, 2026